Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Running

BioForceInk Bioactive reinforcing bioink for hybrid bioprinting of implantable bone

Coordinator
Technion - Israel Institute of Technology, Israel
Runs
1 September 2024 to 28 February 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101189449

What the project is doing

In the project's own words, from its summary on CORDIS.

3D bioprinting is an emerging technique that offers promise for fabricating implantable tissues. Despite significant advancements, the field struggles to replicate the mechanical robustness and biological complexity of native tissues, particularly in applications requiring high mechanical strength such as bone. This proposal introduces 'BioForceInk,' a bioactive reinforcing bioink designed for direct bioprinting alongside a cell-laden hydrogel within a cell-conductive environment.

The microparticle-based bioink is printable at room temperature and solidifies at 37°C, forming a stiff, porous scaffold within the construct. Our preliminary studies demonstrated its excellent printability, mechanical properties, and osteoconductive capabilities in a hybrid bioprinting context. To enhance vascularized bone differentiation in vitro and support bioprinted implant integration and bone recovery in vivo, the bioink will be enriched with osteogenic and vasculogenic factors.

Throughout this project, we aim to develop the growth factor-loaded BioForceInk and utilize it for creating vascularized bone implants by hybrid bioprinting in tandem with cell-laden soft bioink. We will then evaluate the regenerative potential of the bioprinted vascularized bone implants in a critical-size bone loss model. Additionally, we plan to test the technology with industrial partners and prepare it for commercialization by the end of the project.

BioForceInk offers a unique combination of mechanical support and biological activity that facilitates the single-step fabrication of physiologically relevant bone implants. This innovation has the potential to significantly narrow the gap between bioprinting technology and clinical application, contributing to the development of personalized, mechanically robust, and biologically functional bone implants. With its tunable properties, BioForceInk could be further adapted for bioprinting of various tissues, reflecting its broad potential across the field.

Topics

Who is involved

OrganisationCityCountryRole
Technion - Israel Institute of TechnologyHaifaIsraelCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI